Product How it works Pricing Blog FAQ About Contact
Español English
EspañolEnglish
Log inCreate free account
Vertex Pharmaceuticals

Vertex Pharmaceuticals (NASDAQ: VRTX) insider transactions

In the twelve months to 10 November 2026, executives and directors of Vertex Pharmaceuticals reported 94 open-market sales of 354,230 shares ($164.4m) and 0 open-market purchases, by 13 people, according to the Form 4 filings they submitted to the SEC.

Latest transactions

The 20 most recent transactions in Vertex Pharmaceuticals shares reported on Form 4
DateInsiderRoleTransactionSharesPriceHeld afterFiling
6 November 2026Kewalramani ReshmaCEO & PresidentOpen-market sale, 10b5-1 plan−11,866$531.5386,471Form 4
20 October 2026Brennan Daniel J.DirectorGrant or award+795$503.47795Form 4
8 September 2026van Grunsven JasperEVP, CP and NPPOGrant or award+8,682—8,682Form 4
28 August 2026Ambrose KristenSVP & Chief Accounting OfficerGrant or award+5,000—11,624Form 4
27 August 2026Sachs Bruce IDirectorGift−6,000—39,000Form 4
21 July 2026Sachdev AmitEVP Chief Patient & Ext Af OffGrant or award+8,251—66,512Form 4
21 July 2026Tatsis OuraniaEVP, Chief Reg. & Quality Off.Grant or award+8,251—53,572Form 4
2 July 2026McKechnie DuncanEVP, Chief Commercial OfficerOpen-market sale, 10b5-1 plan−1,541$519.0011,001Form 4
2 July 2026Tatsis OuraniaEVP, Chief Reg. & Quality Off.Open-market sale, 10b5-1 plan−1,500$524.9945,321Form 4
1 July 2026Liu JoyEVP and Chief Legal OfficerOpen-market sale, 10b5-1 plan−828$502.7119,131Form 4
26 June 2026Bozic CarmenEVP and CMOOpen-market sale, 10b5-1 plan−596$482.5015,337Form 4
18 June 2026Bozic CarmenEVP and CMOOpen-market sale, 10b5-1 plan−1,020$462.1715,933Form 4
15 June 2026Bozic CarmenEVP and CMOOpen-market sale, 10b5-1 plan−4,062$450.0016,953Form 4
5 June 2026Bozic CarmenEVP and CMOOpen-market sale, 10b5-1 plan−1,745$450.0021,015Form 4
1 June 2026Liu JoyEVP and Chief Legal OfficerOpen-market sale, 10b5-1 plan−828$439.9119,959Form 4
29 May 2026Bozic CarmenEVP and CMOOpen-market sale, 10b5-1 plan−1,974$450.0022,760Form 4
15 May 2026Bozic CarmenEVP and CMOOpen-market sale, 10b5-1 plan−1,354$453.4524,734Form 4
15 May 2026Bunnage Mark E.EVP, Chief Scientific OfficerOpen-market sale, 10b5-1 plan−33$453.457,284Form 4
12 May 2026Bozic CarmenEVP and CMOOpen-market sale, 10b5-1 plan−6,988$450.0026,088Form 4
4 May 2026Bhatia Sangeeta N.DirectorOpen-market sale, 10b5-1 plan−318$423.734,924Form 4

Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.

How to read the table

Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.

Where each row comes from

From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Vertex Pharmaceuticals page; the method, in data sources.

Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.